Polypid
Open
$4.64
Prev. Close
$4.64
High
$4.64
Low
$4.63
Market Snapshot
$72.32M
-2.3
1.04
69
PolyPid Ltd. operates as a phase 3 biopharma company. The company is headquartered in Petah Tikva, Central(Hamerkaz) and currently employs 69 full-time employees. The company went IPO on 2020-06-26. The firm focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Polypid Ltd. experiences a significant increase in short interest, while analysts maintain a 'Moderate Buy' rating and set a target price of $12.25.
PolyPid Ltd. operates as a phase 3 biopharma company. The company is headquartered in Petah Tikva, Central(Hamerkaz) and currently employs 69 full-time employees. The company went IPO on 2020-06-26. The firm focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Recently from Cashu
Couldn't load Cashu news
Something went wrong. Try refreshing the page.